Phase 3 N=1,115 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Five-year Disease-free Survival (DFS) Rate — 85.3; 86.3 percentage of participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=140 Stylet Angle for McGrath Videolaryngoscopy
Intubation
Primary: Time to Intubation — 32.5; 29.3 seconds
Phase 2 N=30 Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
HIV-HCV
Primary: The Percentage of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 90; 80 Percentage of subjects
N/A N=143 Pain and Sensory Changes Assessment in HIV+ Patients
HIV Infections
Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants
Phase 4 N=195 Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
HIV Infection
Primary: Immunogenicity — 22; 25; 344; 686 Geometric Mean antibody titer
Phase 2 N=103 Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Effective Castration Rate Over 25 Weeks — 95; 89 percentage of participants
Phase 2 N=207 Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
Hepatitis B
Primary: Percentage of Participants With Local and Systemic Post-injection Reaction Rates — 38.2; 37.9; 37.2; 33.0 percentage of subjects
Phase 2 N=909 A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
Asthma
Primary: Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period — 0.170…
Phase 4 N=22 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude
Hypertension, Pulmonary · Altitude Sickness
Primary: Mean Pulmonary Artery Pressure — 16.8667; 15.6545; 16.3800; 16.6833 mm Hg
N/A N=33 Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD
Congenital Heart Disease
Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47
Phase 3 N=689 Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612
Infections, Meningococcal
Primary: Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups — 404; 132; 404; 131 Subjects
Phase 3 N=882 Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Asthma
Primary: Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12…
Phase 1 N=72 Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use
Healthy
Primary: Area Under the Concentration-time Curve of the Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz) — 2850; 2790…
Phase 3 N=614 A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Breast Cancer
Primary: Disease-free Survival — 88.6; 88.8; 87.1; 84.7 percentage of participants
Early Phase 1 N=6 Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants